Klearchos K PAPAS

Dr. Klearchos K PAPAS

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
GKGregory Korbutt
Gregory Korbutt
ATAlice A. Tomei
Alice A. Tomei
AGAndres Garcia
Andres Garcia
APAndrew R Pepper
Andrew R Pepper
Paul De VosPaul De Vos
Paul De Vos

1 January 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
KPKlearchos K PAPAS
Klearchos K PAPAS
HLHector De Leon
Hector De Leon
TSThomas M. Suszynski
Thomas M. Suszynski
RJRobert C. Johnson
Robert C. Johnson

14 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
LWLong-Hai Wang
Long-Hai Wang
AEAlexander Ulrich Ernst
Alexander Ulrich Ernst
JFJames Arthur Flanders
James Arthur Flanders
Wanjun LiuWanjun Liu
Wanjun Liu
XWXi Wang
Xi Wang
MMMinglin Ma
Minglin Ma
Cell encapsulation represents a promising therapeutic strategy for many hormone-deficient diseases such as type 1 diabetes (T1D). However, adequate oxygenation of the encapsulated cells remains a challenge, especially in the poorly oxygenated subcutaneous site. Here, we present an encapsulation system that generates oxygen (O2) for the cells from their own waste product, carbon dioxide (CO2), in a self-regulated (i.e., “inverse breathing”) way. We leveraged a gas-solid (CO2–lithium peroxide) reaction that was completely separated from the aqueous cellular environment by a gas permeable membrane. O2 measurements and imaging validated CO2-responsive O2 release, which improved cell survival in hypoxic conditions. Simulation-guided optimization yielded a device that restored normoglycemia of immunocompetent diabetic mice for over 3 months. Furthermore, functional islets were observed in scaled-up device implants in minipigs retrieved after 2 months. This inverse breathing device provides a potential system to support long-term cell function in the clinically attractive subcutaneous site.

10 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KPKlearchos K PAPAS
Klearchos K PAPAS
MBMelena D. Bellin
Melena D. Bellin
DSDavid E. R. Sutherland
David E. R. Sutherland
TSThomas M. Suszynski
Thomas M. Suszynski
JKJennifer P. Kitzmann
Jennifer P. Kitzmann
BHBernhard J. Hering
Bernhard J. Hering
Reliable in vitro islet quality assessment assays that can be performed routinely, prospectively, and are able to predict clinical transplant outcomes are needed. In this paper we present data on the utility of an assay based on cellular oxygen consumption rate (OCR) in predicting clinical islet autotransplant (IAT) insulin independence (II). IAT is an attractive model for evaluating characterization assays regarding their utility in predicting II due to an absence of confounding factors such as immune rejection and immunosuppressant toxicity. Membrane integrity staining (FDA/PI), OCR normalized to DNA (OCR/DNA), islet equivalent (IE) and OCR (viable IE) normalized to recipient body weight (IE dose and OCR dose), and OCR/DNA normalized to islet size index (ISI) were used to characterize autoislet preparations (n = 35). Correlation between pre-IAT islet product characteristics and II was determined using receiver operating characteristic analysis. Preparations that resulted in II had significantly higher OCR dose and IE dose (p<0.001). These islet characterization methods were highly correlated with II at 6–12 months post-IAT (area-under-the-curve (AUC) = 0.94 for IE dose and 0.96 for OCR dose). FDA/PI (AUC = 0.49) and OCR/DNA (AUC = 0.58) did not correlate with II. OCR/DNA/ISI may have some utility in predicting outcome (AUC = 0.72). Commonly used assays to determine whether a clinical islet preparation is of high quality prior to transplantation are greatly lacking in sensitivity and specificity. While IE dose is highly predictive, it does not take into account islet cell quality. OCR dose, which takes into consideration both islet cell quality and quantity, may enable a more accurate and prospective evaluation of clinical islet preparations.

5 February 2013 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
KMKate R Mueller
Kate R Mueller
ABA N Balamurugan
A N Balamurugan
GCGary W Cline
Gary W Cline
RPRebecca L Pongratz
Rebecca L Pongratz
RHRebecca L Hooper
Rebecca L Hooper
KPKlearchos K PAPAS
Klearchos K PAPAS

30 October 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
TSThomas M. Suszynski
Thomas M. Suszynski
EAEfstathios S. Avgoustiniatos
Efstathios S. Avgoustiniatos
KPKlearchos K PAPAS
Klearchos K PAPAS
Intraportal islet transplantation (IT) is not widely utilized as a treatment for type 1 diabetes. Oxygenation of the intraportally transplanted islet has not been studied extensively. We present a diffusion-reaction model that predicts the presence of ananoxiccore and a largerpartly functionalcore within intraportally transplanted islets. Four variables were studied: islet diameter, islet fractional viability, external oxygen partial pressure (P) (in surrounding portal blood), and presence or absence of a thrombus on the islet surface. Results indicate that an islet with average size and fractional viability exhibits an anoxic volume fraction (AVF) of 14% and a function loss of 72% at a low externalP. Thrombus formation increased AVF to 30% and function loss to 92%, suggesting that the effect of thrombosis may be substantial. ExternalPand islet diameter accounted for the greatest overall impact on AVF and loss of function. At our institutions, large human alloislets (>200μm diameter) account for ~20% of total islet number but ~70% of total islet volume; since most of the total transplanted islet volume is accounted for by large islets, most of the intraportal islet cells are likely to be anoxic and not fully functional.